TY - JOUR
TI - MMP-3 mRNA and MMP-3 and MMP-1 proteins in bladder cancer: a comparison with clinicopathologic features and survival.
AU - Nakopoulou, L.
AU - Gakiopoulou, H.
AU - Zervas, A.
AU - Giannopoulou, I.
AU - Constantinides, C.
AU - Lazaris, A. C.
AU - Liapis, H.
AU - Kyriakou, G.
AU - Dimopoulos, C.
JO - Applied immunohistochemistry & molecular morphology : AIMM
PY - 2001
VL - 9
TODO - 2
SP - 130--137
PB - 
SN - null
TODO - 10.1097/00129039-200106000-00005
TODO - Humans, Female, Male, Survival Rate, Aged, Adult, Middle Aged, Aged, 80 and over, Neoplasm Invasiveness, Immunohistochemistry, Disease-Free Survival, Proportional Hazards Models, In Situ Hybridization, Carcinoma, Transitional Cell/*enzymology/metabolism/mortality/pathology, Matrix Metalloproteinase 1/genetics/*metabolism, Matrix Metalloproteinase 3/*metabolism, Stromal Cells/enzymology/metabolism, Urinary Bladder Neoplasms/*enzymology/metabolism/mortality/pathology, Urinary Bladder/enzymology/metabolism/pathology
TODO - Matrix metalloproteinases (MMPs) are proteolytic enzymes important at several points during multistep neoplastic progression. Although MMP-1 and MMP-3 have been  implicated in the progression of various human cancers, their expression in bladder  cancer has not been addressed. Immunohistochemistry (Strept-ABC-HRP method) and in  situ hybridization were performed to detect MMP-1 protein, MMP-3 protein, and MMP-3  mRNA, respectively, in 59 transitional cell bladder carcinomas. To assess the role  of these MMPs in bladder cancer, their expression was evaluated in relation to known  clinicopathologic parameters and patients’ disease-free and overall survival.  Immunoreactivity for MMP-1 and MMP-3 proteins was observed in the cytoplasm of  cancer cells in 30.5% and 24% of samples, respectively. Transcripts for MMP-3 mRNA  were localized in stromal cells in 71.2% of cases and in cancer cells in 49% of  cases. MMP-1 immunoreactivity demonstrated a statistically significant association  with deeply invasive and grade III tumors versus superficial and lower grade tumors.  MMP-3 protein immunoreactivity and MMP-3 mRNA immunolocalization did not associate  with the parameters studied. However, MMP-3 mRNA localization in stromal cells  demonstrated a borderline association with poor patients’ disease-free and overall  survival. In conclusion, the authors’ results demonstrate a differential expression  between MMP-1 and MMP-3 in bladder cancer; MMP-1 appears to participate in  invasiveness and possibly in loss of differentiation in urothelial carcinomas in  contrast to MMP-3.
ER -